steverocks35
Well-known member
- Joined
- Nov 26, 2008
- Messages
- 8,436
- Reaction score
- 1,538
You are not understanding the problems with a RETROSPECTIVE COHORT STUDY. There is so much selection bias and observational bias in a study like that. Especially when studying a drug like this during a pandemic. And we don't even know if the two cohort were similar because they haven't released any Table 1 data.
My point was that study should not even be a data point in your analysis. It's even worse than the French study -- which to your point was not rigorous. You aren't gonna find an answer to the question "Does hydroxychloroquine benefit COVID patients" with a retrospective chart review. You should stop commenting about the effectiveness of the drug until a controlled trial plays out.
You keep screaming for evidence and then using terrible evidence in your arguments. That's all I am saying.
You know what? Fair enough, we can revisit this topic at least when this study has been peer-reviewed and formally published (or not published). I will gladly eat my crow if it's debunked.